CVSI Quote, Financials, Valuation and Earnings

GB Sciences, Inc. has a net margin of -11.73% compared to CV Sciences, Inc.'s net margin of --. CV Sciences, Inc.'s return on equity of -80.15% beat GB Sciences, Inc.'s return on equity of --.

CV Sciences, Inc. has a consensus price target of --, signalling downside risk potential of -1.72%. On the other hand GB Sciences, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that CV Sciences, Inc. has higher upside potential than GB Sciences, Inc., analysts believe CV Sciences, Inc. is more attractive than GB Sciences, Inc..

CV Sciences, Inc. has a beta of 0.316, which suggesting that the stock is 68.426% less volatile than S&P 500. In comparison GB Sciences, Inc. has a beta of 11.330, suggesting its more volatile than the S&P 500 by 1032.978%.

CV Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GB Sciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CV Sciences, Inc. pays -- of its earnings as a dividend. GB Sciences, Inc. pays out -- of its earnings as a dividend.

CV Sciences, Inc. quarterly revenues are $3.3M, which are larger than GB Sciences, Inc. quarterly revenues of --. CV Sciences, Inc.'s net income of -$382K is lower than GB Sciences, Inc.'s net income of -$190.5K. Notably, CV Sciences, Inc.'s price-to-earnings ratio is -- while GB Sciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CV Sciences, Inc. is 0.65x versus 1.26x for GB Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Iovance Biotherapeutics, Inc. has a net margin of -11.73% compared to CV Sciences, Inc.'s net margin of -135.28%. CV Sciences, Inc.'s return on equity of -80.15% beat Iovance Biotherapeutics, Inc.'s return on equity of -54.43%.

CV Sciences, Inc. has a consensus price target of --, signalling downside risk potential of -1.72%. On the other hand Iovance Biotherapeutics, Inc. has an analysts' consensus of $9.11 which suggests that it could grow by 254.52%. Given that Iovance Biotherapeutics, Inc. has higher upside potential than CV Sciences, Inc., analysts believe Iovance Biotherapeutics, Inc. is more attractive than CV Sciences, Inc..

CV Sciences, Inc. has a beta of 0.316, which suggesting that the stock is 68.426% less volatile than S&P 500. In comparison Iovance Biotherapeutics, Inc. has a beta of 0.765, suggesting its less volatile than the S&P 500 by 23.531%.

CV Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Iovance Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CV Sciences, Inc. pays -- of its earnings as a dividend. Iovance Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

CV Sciences, Inc. quarterly revenues are $3.3M, which are smaller than Iovance Biotherapeutics, Inc. quarterly revenues of $67.5M. CV Sciences, Inc.'s net income of -$382K is higher than Iovance Biotherapeutics, Inc.'s net income of -$91.3M. Notably, CV Sciences, Inc.'s price-to-earnings ratio is -- while Iovance Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CV Sciences, Inc. is 0.65x versus 3.40x for Iovance Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Protokinetix, Inc. has a net margin of -11.73% compared to CV Sciences, Inc.'s net margin of --. CV Sciences, Inc.'s return on equity of -80.15% beat Protokinetix, Inc.'s return on equity of -111.59%.

CV Sciences, Inc. has a consensus price target of --, signalling downside risk potential of -1.72%. On the other hand Protokinetix, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that CV Sciences, Inc. has higher upside potential than Protokinetix, Inc., analysts believe CV Sciences, Inc. is more attractive than Protokinetix, Inc..

CV Sciences, Inc. has a beta of 0.316, which suggesting that the stock is 68.426% less volatile than S&P 500. In comparison Protokinetix, Inc. has a beta of 0.614, suggesting its less volatile than the S&P 500 by 38.569%.

CV Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protokinetix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CV Sciences, Inc. pays -- of its earnings as a dividend. Protokinetix, Inc. pays out -- of its earnings as a dividend.

CV Sciences, Inc. quarterly revenues are $3.3M, which are larger than Protokinetix, Inc. quarterly revenues of --. CV Sciences, Inc.'s net income of -$382K is lower than Protokinetix, Inc.'s net income of -$84.9K. Notably, CV Sciences, Inc.'s price-to-earnings ratio is -- while Protokinetix, Inc.'s PE ratio is 23.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CV Sciences, Inc. is 0.65x versus -- for Protokinetix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics, Inc. has a net margin of -11.73% compared to CV Sciences, Inc.'s net margin of -316.61%. CV Sciences, Inc.'s return on equity of -80.15% beat Plus Therapeutics, Inc.'s return on equity of --.

CV Sciences, Inc. has a consensus price target of --, signalling downside risk potential of -1.72%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 1898.55%. Given that Plus Therapeutics, Inc. has higher upside potential than CV Sciences, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than CV Sciences, Inc..

CV Sciences, Inc. has a beta of 0.316, which suggesting that the stock is 68.426% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.364%.

CV Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CV Sciences, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.

CV Sciences, Inc. quarterly revenues are $3.3M, which are larger than Plus Therapeutics, Inc. quarterly revenues of $1.4M. CV Sciences, Inc.'s net income of -$382K is higher than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, CV Sciences, Inc.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CV Sciences, Inc. is 0.65x versus 4.41x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.